CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
For the assessment of the combination of CEA-TCB with CEA-4-1BBL, co-stimulatory antibody fusion protein in vitro assays are not sufficient to fully capture the complex relationships affecting efficacy. Thus, screening with different cell assays and in vivo efficacy studies in combination with CEA-TCB are essential to select the best candidate. Based on the totality of data on the T84.66-LCHA-4-1BBL antibody fusion protein comprising the CEACAM5 antibody, T84.66-LCHA was selected as the optimal combination partner for CEA-TCB.
Authors
- Marina Bacac (ORCID: https://orcid.org/0000-0003-0581-9579)
- Sara Colombetti (ORCID: https://orcid.org/0000-0002-7375-8600)
- Esther Bommer
- Regula B. Buser
- Claudia Ferrara
- Pablo Umaña (ORCID: https://orcid.org/0000-0001-8206-2771)
- Christina Claus (ORCID: https://orcid.org/0000-0001-6316-5855)
- Grégory La Sala (ORCID: https://orcid.org/0000-0002-7747-0428)
- Christian Klein (ORCID: https://orcid.org/0000-0001-7594-7280)
- Valeria Nicolini (ORCID: https://orcid.org/0000-0003-4306-7849)
- Johannes Sam (ORCID: https://orcid.org/0000-0002-7455-0609)
- Sabine M. Lang
- R. Albrecht
Institutions
- Roche (Switzerland) (CH)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Antibodies
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3390/antib14040096
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00